Holen Sie sich die Stockscreener-App
1.58
3.66%
-0.06
Vorhandelsmarkt:
1.64
0.06
+3.80%
Schlusskurs vom Vortag:
$1.64
Offen:
$1.66
24-Stunden-Volumen:
2.09M
Relative Volume:
1.05
Marktkapitalisierung:
$80.17M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-67.68M
KGV:
-0.9518
EPS:
-1.66
Netto-Cashflow:
$-54.24M
1W Leistung:
-3.07%
1M Leistung:
-11.73%
6M Leistung:
-37.80%
1J Leistung:
-78.03%
1-Tages-Spanne:
$1.58
$1.675
1-Wochen-Bereich:
$1.58
$1.7306
52-Wochen-Spanne:
$0.9857
$7.28
Cabaletta Bio Inc Stock (CABA) Company Profile
Firmenname
Cabaletta Bio Inc
Sektor
Branche
Telefon
(267) 759-3100
Adresse
2929 ARCH STREET, PHILADELPHIA, PA
Vergleichen Sie CABA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
1.58 | 146.61M | 0 | -67.68M | -54.24M | -1.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-02-05 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Eingeleitet | William Blair | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | Stifel | Buy |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-07-18 | Eingeleitet | Guggenheim | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-01-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Eingeleitet | Cowen | Outperform |
| 2019-11-19 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
What analysts say about Cabaletta Bio Inc. stockRapid growth trajectories - jammulinksnews.com
What drives Cabaletta Bio Inc. stock priceFree Stock Market Trend Analysis - jammulinksnews.com
Cabaletta Bio Inc. Stock Analysis and ForecastFree Investment Timing Strategies - jammulinksnews.com
Why Cabaletta Bio Inc. stock attracts strong analyst attentionFree Best Performing Stock Alerts - Newser
Will Cabaletta Bio Inc. stock benefit from interest rate changesPredictable High Return Trades - Newser
Is Cabaletta Bio Inc. a good long term investmentPhenomenal wealth increase - Autocar Professional
Cabaletta Bio’s RESET-SLE Study: A Promising Step in Lupus Treatment - TipRanks
Cabaletta Bio’s RESET-MG Study: A Potential Game-Changer for Myasthenia Gravis Treatment - TipRanks
What institutions are buying Cabaletta Bio Inc. stock nowFree Predictions - Newser
Cabaletta Bio’s RESET-Myositis Study: A Promising Step in Autoimmune Treatment - TipRanks
Cabaletta Bio’s RESET-MG Study: A Promising Step in Myasthenia Gravis Treatment - TipRanks
How Cabaletta Bio Inc. stock performs during market volatilityFree Wealth-Building Investment Strategies - beatles.ru
What makes Cabaletta Bio Inc. stock price move sharplyCapital Growth Picks - Newser
Cabaletta Bio’s RESET-Myositis Study: A Potential Game-Changer in Autoimmune Disease Treatment - TipRanks
Cabaletta Bio (NASDAQ:CABA) Stock Price Up 1.3%Here's What Happened - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of “Buy” from Analysts - Defense World
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Cabaletta Bio, Inc.(NasdaqGS: CABA) dropped from Russell 2000 Dynamic Index - MarketScreener
Cabaletta Bio, Inc.(NasdaqGS: CABA) dropped from Russell Microcap Growth Index - MarketScreener
Cabaletta Bio Prices Public Offering to Raise $100 Million - MSN
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Cabaletta Bio's SWOT analysis: CAR-T pioneer's stock faces market skepticism - Investing.com Australia
Cabaletta Bio’s SWOT analysis: CAR-T pioneer’s stock faces market skepticism - Investing.com Australia
Cabaletta Bio’s SWOT analysis: CAR-T pioneer’s stock faces market skepticism By Investing.com - Investing.com South Africa
Cabaletta Bio's 10% Surge: A Mystery Move Amid Biotech Sector Decline - AInvest
Cantor Fitzgerald Weighs in on Cabaletta Bio FY2026 Earnings - MarketBeat
Cabaletta Bio's (CABA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Cabaletta Bio Reports Promising Data from RESET Trials for Transformative Autoimmune Therapy - MSN
Finanzdaten der Cabaletta Bio Inc-Aktie (CABA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):